Investigating how empagliflozin affects heart function in adults at risk for heart failure
Effects of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
This study is looking at how the medication empagliflozin might help improve heart function in adults who are at risk for heart failure but don’t have it yet, and we’re inviting people from the University of Minnesota's Cardiology clinic to join us for this 9-month trial.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11067755 on NIH RePORTER |
What this research studies
This research explores the effects of empagliflozin, a medication that inhibits sodium-glucose cotransporters, on the function of the left atrium in adults who are at risk for heart failure but do not have a diagnosis of heart failure or diabetes. The study will involve a 9-month double-blind, placebo-controlled trial with 80 participants, utilizing advanced echocardiography techniques to assess changes in heart function. By examining the relationship between empagliflozin and left atrial function, the research aims to uncover potential therapeutic benefits for preventing heart failure. Participants will be recruited from the Cardiology clinic at the University of Minnesota.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are at risk for heart failure but do not have a current diagnosis of heart failure or diabetes.
Not a fit: Patients who already have a diagnosis of heart failure or diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for preventing heart failure in at-risk individuals.
How similar studies have performed: Previous research has shown that SGLT2 inhibitors can reduce cardiovascular events, indicating potential for success in similar approaches.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Van't Hof, Jeremy R. — University of Minnesota
- Study coordinator: Van't Hof, Jeremy R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.